{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:20Z","timestamp":1793198660281,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Considerable evidence shows that circular RNAs (circRNAs) play an important role in tumor development. However, their function in intrahepatic cholangiocarcinoma (ICC) metastasis and the underlying mechanisms are incompletely understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>circNFIB (hsa_circ_0086376, termed as cNFIB hereafter) was identified in human ICC tissues through circRNAs sequencing. The biological role of cNFIB was determined in vitro and in vivo by gain or loss of functional experiments. Fluorescence in situ hybridization (FISH), RNA immunoprecipitation (RIP) and RNA pull-down assays were conducted to analyze the interaction of cNFIB with dual specificity mitogen-activated protein kinase kinase1 (MEK1). Duolink in situ proximity ligation assay (PLA) and coimmunoprecipitation (co-IP) assay were used to investigate the effects of cNFIB on the interaction between MEK1 and mitogen-activated protein kinase 2 (ERK2). Finally, a series of in vitro and in vivo experiments were performed to explore the influences of cNFIB on the anti-tumor activity of trametinib (a MEK inhibitor).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>cNFIB was significantly down-regulated in human ICC tissues with postoperative metastases. The loss of cNFIB was highly associated with aggressive characteristics and predicted unfavorable prognosis in ICC patients. Functional studies revealed that cNFIB inhibited the proliferation and metastasis of ICC cells in vitro and in vivo. Mechanistically, cNFIB competitively interacted with MEK1, which induced the dissociation between MEK1 and ERK2, thereby resulting in the suppression of ERK signaling and tumor metastasis. Moreover, we found that ICC cells with high levels of cNFIB held the potential to delay the trametinib resistance. Consistently, in vivo and in vitro studies demonstrated that cotreatment with trametinib and lentivirus vector encoding cNFIB showed greater inhibitory effect than isolated trametinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings identified that cNFIB played a key role in ICC growth and metastasis by regulating MEK1\/ERK signaling. Given the efficacy of cNFIB modulation on ICC suppression and trametinib sensitivity, cNFIB appears to be a potential therapeutic molecule for ICC treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-021-01482-9","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:24:24Z","timestamp":1642407864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["CircNFIB inhibits tumor growth and metastasis through suppressing MEK1\/ERK signaling in intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Jinpeng","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-9690","authenticated-orcid":false,"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"1482_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;(71):209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"1482_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"1482_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, Chou JF, G\u00f6nen M, Boucher TM, et al. Assessment of hepatic arterial infusion of Floxuridine in combination with systemic gemcitabine and Oxaliplatin in patients with Unresectable intrahepatic Cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:60\u20137.","journal-title":"JAMA Oncol"},{"key":"1482_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2016.05.019","volume":"223","author":"A Doussot","year":"2016","unstructured":"Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, et al. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg. 2016;223:493\u2013505 e492.","journal-title":"J Am Coll Surg"},{"key":"1482_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2890","volume":"32","author":"WR Jeck","year":"2014","unstructured":"Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453\u201361.","journal-title":"Nat Biotechnol"},{"key":"1482_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.celrep.2014.12.019","volume":"10","author":"A Ivanov","year":"2015","unstructured":"Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10:170\u20137.","journal-title":"Cell Rep"},{"key":"1482_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","volume":"58","author":"A Rybak-Wolf","year":"2015","unstructured":"Rybak-Wolf A, Stottmeister C, Gla\u017ear P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870\u201385.","journal-title":"Mol Cell"},{"key":"1482_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30671","volume":"70","author":"Q Li","year":"2019","unstructured":"Li Q, Pan X, Zhu D, Deng Z, Jiang R, Wang X. Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p\/PKM2 Axis under hypoxic stress. Hepatology. 2019;70:1298\u2013316.","journal-title":"Hepatology"},{"key":"1482_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep.31068","volume":"72","author":"ZQ Hu","year":"2020","unstructured":"Hu ZQ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis. Hepatology. 2020;72:906\u201322.","journal-title":"Hepatology"},{"key":"1482_CR10","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1038\/s41467-019-12651-2","volume":"10","author":"RX Chen","year":"2019","unstructured":"Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10:4695.","journal-title":"Nat Commun"},{"key":"1482_CR11","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41467-018-06862-2","volume":"9","author":"M Zhang","year":"2018","unstructured":"Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9:4475.","journal-title":"Nat Commun"},{"key":"1482_CR12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/hep.31493","volume":"73","author":"Y Xu","year":"2021","unstructured":"Xu Y, Leng K, Yao Y, Kang P, Liao G, Han Y, et al. A circular RNA, Cholangiocarcinoma-associated circular RNA 1, contributes to Cholangiocarcinoma progression, induces angiogenesis, and disrupts vascular endothelial barriers. Hepatology. 2021;73:1419\u201335.","journal-title":"Hepatology"},{"key":"1482_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1482_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.120.049715","volume":"143","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Xia L, Fan S, Zheng J, Qin J, Fan X, et al. Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation. Circulation. 2021;143:354\u201371.","journal-title":"Circulation"},{"key":"1482_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-020-01160-2","volume":"19","author":"M Jie","year":"2020","unstructured":"Jie M, Wu Y, Gao M, Li X, Liu C, Ouyang Q, et al. CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Mol Cancer. 2020;19:56.","journal-title":"Mol Cancer"},{"key":"1482_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41556-021-00639-4","volume":"23","author":"X Gao","year":"2021","unstructured":"Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. Nat Cell Biol. 2021;23:278\u201391.","journal-title":"Nat Cell Biol"},{"key":"1482_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","volume":"6","author":"JY Fang","year":"2005","unstructured":"Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322\u20137.","journal-title":"Lancet Oncol"},{"key":"1482_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75:50\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"key":"1482_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/02699050500284218","volume":"24","author":"S Yoon","year":"2006","unstructured":"Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21\u201344.","journal-title":"Growth Factors"},{"key":"1482_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1482_CR21","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/ncb1994","volume":"11","author":"A von Kriegsheim","year":"2009","unstructured":"von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, et al. Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol. 2009;11:1458\u201364.","journal-title":"Nat Cell Biol"},{"key":"1482_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829\u201340.","journal-title":"Gastroenterology"},{"key":"1482_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-Centre, phase 2 clinical trial. Lancet Oncol. 2017;18:464\u201372.","journal-title":"Lancet Oncol"},{"key":"1482_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","volume":"27","author":"G Moriceau","year":"2015","unstructured":"Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015;27:240\u201356.","journal-title":"Cancer Cell"},{"key":"1482_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.cell.2016.05.052","volume":"166","author":"SK Denny","year":"2016","unstructured":"Denny SK, Yang D, Chuang CH, Brady JJ, Lim JS, Gr\u00fcner BM, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166:328\u201342.","journal-title":"Cell"},{"key":"1482_CR26","doi-asserted-by":"publisher","first-page":"e13162","DOI":"10.15252\/emmm.202013162","volume":"13","author":"F Zilli","year":"2021","unstructured":"Zilli F, Marques Ramos P. Auf der Maur P, Jehanno C, Sethi a, Coissieux MM, Eichlisberger T, Sauteur L, Rouchon a, Bonapace L, et al: the NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells. EMBO Mol Med. 2021;13:e13162.","journal-title":"EMBO Mol Med"},{"key":"1482_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9:329\u201341.","journal-title":"Cancer Discov"},{"key":"1482_CR28","doi-asserted-by":"publisher","first-page":"18101","DOI":"10.1073\/pnas.0608849103","volume":"103","author":"MA Emrick","year":"2006","unstructured":"Emrick MA, Lee T, Starkey PJ, Mumby MC, Resing KA, Ahn NG. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity. Proc Natl Acad Sci U S A. 2006;103:18101\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1482_CR29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","volume":"3","author":"EJ Morris","year":"2013","unstructured":"Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3:742\u201350.","journal-title":"Cancer Discov"},{"key":"1482_CR30","doi-asserted-by":"publisher","first-page":"34985","DOI":"10.1038\/srep34985","volume":"6","author":"X Chen","year":"2016","unstructured":"Chen X, Han P, Zhou T, Guo X, Song X. Li Y: circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. 2016;6:34985.","journal-title":"Sci Rep"},{"key":"1482_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1482_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1126\/science.8052857","volume":"265","author":"SJ Mansour","year":"1994","unstructured":"Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994;265:966\u201370.","journal-title":"Science"},{"key":"1482_CR33","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1093\/bioinformatics\/btt495","volume":"29","author":"F Agostini","year":"2013","unstructured":"Agostini F, Zanzoni A, Klus P, Marchese D, Cirillo D. Tartaglia GG: catRAPID omics: a web server for large-scale prediction of protein-RNA interactions. Bioinformatics. 2013;29:2928\u201330.","journal-title":"Bioinformatics"},{"key":"1482_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/bfgp\/els022","volume":"11","author":"JL Bromberg-White","year":"2012","unstructured":"Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Brief Funct Genomics. 2012;11:300\u201310.","journal-title":"Brief Funct Genomics"},{"key":"1482_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"key":"1482_CR36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland \u00c5, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307\u201316.","journal-title":"Lancet Oncol"},{"key":"1482_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid Cancer. J Clin Oncol. 2018;36:7\u201313.","journal-title":"J Clin Oncol"},{"key":"1482_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","volume":"75","author":"G Cristinziano","year":"2021","unstructured":"Cristinziano G, Porru M, Lamberti D, Buglioni S, Rollo F, Amoreo CA, et al. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. J Hepatol. 2021;75:351\u201362.","journal-title":"J Hepatol"},{"key":"1482_CR39","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234\u201343.","journal-title":"Lancet Oncol"},{"key":"1482_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ccell.2019.12.007","volume":"37","author":"D Hanniford","year":"2020","unstructured":"Hanniford D, Ulloa-Morales A, Karz A, Berzoti-Coelho MG, Moubarak RS, S\u00e1nchez-Sendra B, et al. Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020;37:55\u201370 e15.","journal-title":"Cancer Cell"},{"key":"1482_CR41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal L, Shi L, Liu LY. Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, et al: TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic Cholangiocarcinoma. Cancer Discov. 2019;9:1064\u201379.","journal-title":"Cancer Discov"},{"key":"1482_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943\u201362.","journal-title":"Cancer Discov"},{"key":"1482_CR43","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/bjc.2017.119","volume":"116","author":"RT Shroff","year":"2017","unstructured":"Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017;116:1402\u20137.","journal-title":"Br J Cancer"},{"key":"1482_CR44","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jhep.2009.01.024","volume":"50","author":"C Wang","year":"2009","unstructured":"Wang C, Maass T, Krupp M, Thieringer F, Strand S, W\u00f6rns MA, et al. A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol. 2009;50:1122\u201331.","journal-title":"J Hepatol"},{"key":"1482_CR45","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1038\/s41467-019-11162-4","volume":"10","author":"Z Cheng","year":"2019","unstructured":"Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, et al. He J, et al: circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nat Commun. 2019;10:3200.","journal-title":"Nat Commun"},{"key":"1482_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71:428\u201342.","journal-title":"Mol Cell"},{"key":"1482_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"WY Zhou","year":"2020","unstructured":"Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:172.","journal-title":"Mol Cancer"},{"key":"1482_CR48","doi-asserted-by":"crossref","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020, 17:557\u2013588.","DOI":"10.1038\/s41575-020-0310-z"},{"key":"1482_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","volume":"7","author":"A Jain","year":"2016","unstructured":"Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016;7:797\u2013803.","journal-title":"J Gastrointest Oncol"},{"key":"1482_CR50","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1186\/s12943-023-01836-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01482-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T10:04:03Z","timestamp":1691834643000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01482-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01482-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-023-01836-5","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-023-01836-5","URL":"https:\/\/doi.org\/10.1186\/s12943-023-01836-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols used in this study were approved by the Ethical Review Committees of Sichuan University (permission number: 2017\u2013184), and written informed consent was provided from all the patients. The animal studies were authorized by the Animal Ethic Review Committees of the West China Hospital, China (permission number: 2020413A). All animal experiments were strictly implemented in compliance with the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}